Registrera för att skapa bevakningar för instrument,
ekonomiska händelser och innehåll av författare som följs
Gratis registrering Har du redan ett konto? Logga in
Värdering
Alla instrumenttyper
- Alla instrumenttyper
- Index
- Aktier
- ETF
- Fonder
- Råvaror
- Valutor
- Krypto
- Obligationer
- Certifikat
Prova en annan sökning
🤑 Det blir inte mer prisvärt. Hämta detta Black Friday-erbjudande med 60 % RABATT innan det försvinner…
HÄMTA REA
Axa Framlington Biotech Fund - Z Accumulation (0P0000XMRD)
Lägg till/Ta bort från en portfölj
Lägg till portföljen
5,510
+0,070
+1,23%
26/11 - Fördröjd data. Valuta i GBP
- Morningstar-värdering:
- Totala tillgångar: 341,12M
AXA Framlington Biotech Fund GBP Z Acc
5,510
+0,070
+1,23%
- Översikt
- Profil
- Historiska data
- Innehav
0P0000XMRD Översikt
På denna sida hittar du en djupgående profil av Axa Framlington Biotech Fund - Z Accumulation. Läs om viktig ledning, totala tillgångar, investeringsstrategi och kontaktinformation om 0P0000XMRD tillsammans med annan information.
Investeringsstrategi
Att ge kapitaltillväxt på lång sikt genom investeringar i huvudsak företag inom bioteknik, genetiska och medicinska forsknings industrier över hela världen. Fonden investerar i cirka 90-100 företag.
Kontaktinformation
Adress
100, Esplanade du Général de Gaulle
Paris, 92932
France
Paris, 92932
France
Telefon
+33 1 44 45 70 00
Fax
Paris
Verkställande ledning
| Namn | Titel | Sedan | Till |
|---|---|---|---|
| Chris Eccles | Research Analyst | 2024 | Nu |
| Biografi | Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector. Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist. Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford. | ||
| Cinney Zhang | - | 2024 | Nu |
| Catherine Tennyson | - | 2024 | Nu |
| Cinney Zhang | - | 2023 | 2024 |
| Linden Thomson | - | 2012 | 2024 |
| Peter Hughes | Portfolio Manager | 2001 | 2023 |
| Biografi | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
| Dani Saurymper | - | 2015 | 2020 |
| Biografi | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. | ||
| Gemma Game | - | 2011 | 2015 |
| Deane Donnigan | clinical Specialist | 2010 | 2011 |
| Biografi | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
| Andy Smith | Portfolio manager | 2009 | 2010 |
| Biografi | Andy joined AXA Framlington in April 2008 as Portfolio Manager within the healthcare team with specific responsibility for the AXA Framlington Biotech Fund. Previously, he spent three years at SV Life Sciences where he was responsible for managing a global biotechnology investment fund. From 2004 to 2005 he worked at Schroders as Director and Fund Manager, Global Equities. Between 2002 and 2004 he worked within the Asset Management division of the 3i Group as Investment Manager and then Director. | ||
Skriv dina tankar om Axa Framlington Biotech Fund - Z Accumulation
Aär du säker på att du vill ta bort det här diagrammet?
Radera Avbryt
Ersätt det bifogade diagrammet med ett nytt?
Byt ut Avbryt
Riktlinjer för kommentarer
Lägg till diagram till kommentar
Bekräfta blockering
Är du säker på att du vill blockera %USER_NAME%?
Genom att blockera kan du och %USER_NAME% inte se varandras inlägg på Investing.com.
%USER_NAME% lyckades läggas till i din Blockeringslista
Eftersom du precis avblockerat denna person måste du vänta 48 timmar för att kunna förnya blockeringen.
Rapportera den här kommentaren
Jag anser att denna kommentar är:
Kommentar flaggad
Tack!
Rapporten har skickats till våra moderatorer för granskning